摘要
Background: Enthesitis, characterized by inflammation at the sites where tendons, ligaments, or joint capsules insert into bone, is a key hallmark of spondyloarthritis (SpA), encompassing both axial SpA (axSpA) and psoriatic arthritis (PsA). Its accurate assessment is essential for effective diagnosis, management, and monitoring of disease activity and treatment response. However, traditional assessment methods relying primarily on physical examination are hindered by low specificity, underscoring the limitations of this approach in reliably evaluating enthesitis [1]. While ultrasound offers greater accuracy by detecting subclinical inflammation, it does not provide a complete picture of the pathology or its impact on patient symptoms and functional status when used in isolation. To bridge this gap, the DEUS Enthesitis Index (DEI) was developed as a novel scoring system that integrates the strengths of both ultrasound and physical examination into a unified, comprehensive tool. Objectives: 1To developed a composite score, the DEUS Enthesitis Index, incorporating ultrasound-detected active enthesitis and clinical examination findings. 2To evaluate the correlation of DEI with established SpA disease activity indices, patient-reported outcomes, and structural damage detected on ultrasound. 3To compare the performance of DEI against the Leeds Enthesitis Index (LEI), a widely used clinical tool for assessing enthesitis. Methods: A cross-sectional, multicentric study involving 20 rheumatology centers across 11 countries recruited 413 SpA patients (224 axSpA, 189 PsA). Exclusion criteria included recent lower limb trauma or surgery, intense physical activity in the two weeks before enrolment, or fibromyalgia. Bilateral assessment of five lower limb entheseal sites—quadriceps tendon, proximal and distal patellar tendons, Achilles tendon, and plantar fascia—was performed using standardized physical examination and ultrasound protocols. DEI scores were calculated by assigning 1.0 for clinical enthesitis (tenderness upon pressure, mobilization, or contraction against resistance, with or without swelling at the enthesis) and 1.0 for ultrasound-detected active enthesitis as previously defined by our group [2], yielding a maximum score of 20 per patient. Regression analyses evaluated correlations between DEI and disease activity indices (ASDAS, BASDAI, DAPSA), CRP levels, patient-reported outcomes (HAQ, VAS pain), and ultrasound-detected structural damage (enthesophytes, bone erosions). Model performance was compared using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Results: The median DEI among SpA patients was 1.0 (interquartile range: 0.0–3.0). Higher DEI values were observed at the Achilles tendon enthesis compared to other sites, underscoring the importance of this entheseal site in SpA clinical manifestations. DEI correlated significantly with markers of axSpA disease activity, including ASDAS (rho=0.386), BASDAI (rho=0.402), and CRP levels (rho=0.117, p=0.018). In contrast, no correlation was observed between DEI and DAPSA values, emphasizing the distinct domains of joint and entheseal involvement in SpA. Strong associations were observed between DEI and with patient-reported outcomes, including VAS global pain (rho=0.303, p<0.001), HAQ (rho=0.294, p<0.001) and with structural damage identified on ultrasound (enthesophytes, OR=1.58, 95% CI: 1.34–1.94; bone erosions, OR=1.35, 95% CI: 1.19–1.54; both p<0.001). Compared to the LEI, DEI values demonstrated significantly stronger correlations with C-reactive protein levels and a more robust association with ultrasound-detected structural damage at the enthesis, including enthesophytes and bone erosions. Conversely, LEI scores exhibited significantly stronger correlations with indices of SpA disease activity. A comparison of DEI and LEI models across various disease outcomes in SpA patients is presented in Table 1. Conclusion: The DEUS Enthesitis Index (i.e., DEI) represents a novel, integrative tool that combines the sensitivity of physical examination with the specificity of ultrasound to provide a comprehensive assessment of enthesitis in SpA. Its strong correlations with objective inflammatory markers and structural damage highlight its potential utility in clinical practice and research settings. Future longitudinal studies are warranted to assess its responsiveness to treatment and predictive value for long-term outcomes. REFERENCES: [1] Helliwell PS. Assessment of Enthesitis in Psoriatic Arthritis. J Rheumatol. 2019. [2] Di Matteo A, et al. Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study. Ann Rheum Dis. 2024. Table 1. Comparison of for DEI and LEI models across various disease outcomes in SpA patients, all the models are adjusted for age and sex. Acronyms. ASDAS : Ankylosing Spondylitis Disease Activity Score. axSpA: axial spondyloarthritis. BASDAI : Bath Ankylosing Spondylitis Disease Activity Index. CI : confidence interval. CRP : C-reactive protein. DAPSA : Disease Activity in Psoriatic Arthritis. DEI : DEUS enthesitis index. HAQ : Health Assessment Questionnaire Disability-Index. LEI : Leeds Enthesitis Index. PsA : psoriatic arthritis. SpA : spondyloarthritis. US : ultrasound. VAS : Visual Analogue Scale. Acknowledgements: NIL . Disclosure of Interests: Andrea Di Matteo Janssen, Stefano Di Donato: None declared , Emilio Filippucci AbbVie, Amgen, BMS, Janssen, Lilly, Novartis, Pfizer and Union Chimique Belge Pharm. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.